journal
https://read.qxmd.com/read/37978893/the-promise-of-novel-treatments-for-severe-chronic-neutropenia
#21
REVIEW
David C Dale, Audrey Anna Bolyard, Vahagn Makaryan
INTRODUCTION: Severe chronic neutropenia, i.e. absolute neutrophil count (ANC) less than 0.5 × 109 /L, is a serious health problem because it predisposes patients to recurrent bacterial infections. Management radically changed with the discovery that granulocyte colony-stimulating factor (G-CSF) could be used to effectively treat most patients; therapy required regular subcutaneous injections. In the early days of G-CSF therapy, there were concerns that it might somehow overstimulate the bone marrow and cause myelodysplasia (MDS) or acute myeloid leukemia (AML)...
November 18, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37978882/challenges-facing-minimal-residual-disease-testing-for-acute-myeloid-leukemia-and-promising-strategies-to-overcome-them
#22
REVIEW
Si-Qi Li, Man Chen, Xi-Yi Huang, Hui Wang, Ying-Jun Chang
INTRODUCTION: Minimal residual disease (MRD) has been an important biomarker for relapse prediction and treatment choice in patients with acute myeloid leukemia (AML). False-positive or false-negative MRD results due to the low specificity and sensitivity of techniques such as multiparameter flow cytometry (MFC), real-time quantitative polymerase chain reaction, and next-generation sequencing, as well as the biological characteristics of residual leukemia cells, including antigen shift, clone involution, heterogeneous genome of the blast cells, and lack of specific targets, all restrict the clinical use of MRD...
November 18, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37975720/in-the-era-of-primary-prophylaxis-in-hemophilia-what-types-of-orthopedic-surgical-interventions-have-been-published-in-the-2020-2023-period-and-in-which-countries
#23
REVIEW
E Carlos Rodriguez-Merchan
INTRODUCTION: Primary prophylaxis has significantly reduced the number of orthopedic surgical procedures performed on patients with hemophilia (PWH) worldwide. However, studies on orthopedic surgery in PWH are still being published in the medical literature. AREAS COVERED: The aim of this article is to determine the types of orthopedic surgical interventions in PWH published between 2020 and 2023 and the countries in which they are published. EXPERT OPINION: The following orthopedic surgical procedures are still performed on PWH: total knee, ankle, elbow and hip arthroplasty, ankle fusion, ankle distraction, and the surgical removal of hemophilic pseudotumors...
November 17, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37955142/use-of-direct-oral-anticoagulants-and-low-molecular-weight-heparin-in-venous-thromboembolism-associated-with-cancer-real-world-evidence-in-argentina
#24
JOURNAL ARTICLE
M M Clavijo, J I Ruiz, C Muñoz, A Vicente Reparaz M de Los, M A Acuña, C E Casali, M F Aizpurua, C V Mahuad, M E Zerga, A Ventura, G M Garate
BACKGROUND: Venous thromboembolism (VTE) and major bleeding (MB) are common in cancer patients. Reduced-doses of antithrombotics as secondary prophylaxis have limited data. This work aims to describe and to compare treatments and outcomes for cancer-associated VTE. RESEARCH DESIGN AND METHODS: Retrospective study. Adults with cancer-associated VTE were included. After 3-6 months of full-doses of anticoagulants, three strategies were considered: A) lowering the doses; B) maintaining full-doses; C) stopping treatment...
November 13, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37937914/total-elbow-arthroplasty-in-hemophilia-a-high-risk-surgical-procedure
#25
EDITORIAL
E Carlos Rodriguez-Merchan
No abstract text is available yet for this article.
November 8, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37906445/the-delicate-balance-of-graft-versus-leukemia-and-graft-versus-host-disease-after-allogeneic-hematopoietic-stem-cell-transplantation
#26
REVIEW
Katie Maurer, Robert J Soiffer
INTRODUCTION: The curative basis of allogeneic hematopoietic stem cell transplantation (HSCT) relies in part upon the graft versus leukemia (GvL) effect, whereby donor immune cells recognize and eliminate recipient malignant cells. However, alloreactivity of donor cells against recipient tissues may also be deleterious. Chronic graft versus host disease (cGvHD) is an immunologic phenomenon wherein alloreactive donor T cells aberrantly react against host tissues, leading to damaging inflammatory symptoms...
October 31, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37902242/the-role-of-staging-in-multiple-myeloma
#27
JOURNAL ARTICLE
Leonid L Yavorkovsky
INTRODUCTION: The importance of cancer staging is determined by how accurately it can predict prognosis, and how useful it is for treatment decisions. Compared to other malignancies, multiple myeloma (MM) staging proved more challenging because of unreliable prognostic factors and wide-ranging life expectancy. As traditional MM staging continues to evolve, it requires reassessment of its prognostic and predictive value. AREAS COVERED: The studies that included prognostic and predictive value of MM stages from 1975 through 2023 were selected for this review using PubMed, MEDLINE platforms...
October 30, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37897182/sequencing-novel-agents-in-the-treatment-of-classical-hodgkin-lymphoma
#28
REVIEW
Burhan Ferhanoglu, Murat Özbalak
INTRODUCTION: Classical Hodgkin lymphoma (cHL) is a curable disease, with durable remission achieved in about 80% of patients following first-line treatment. Three new drugs were introduced to the daily use in cHL: brentuximab vedotin (BV), nivolumab and pembrolizumab. All three drugs were initially approved for the treatment of relapsed/refractory cHL (RRHL) and with their promising outcomes, they are now incorporated in different stages of the treatment. AREAS COVERED: We performed a literature search using PubMed on all cHL studies investigating BV and CPIs within the past 10 years...
October 28, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37888882/development-of-cd30-car-t-cells-in-refractory-or-relapsed-hodgkin-s-lymphoma
#29
REVIEW
Xiao Chen Ma, Xiao Lv, Ying Li
INTRODUCTION: After therapy, approximately 15% of individuals with Hodgkin's lymphoma (HL) develop relapsed or drug-resistant Hodgkin's lymphoma (r/rHL). r/rHL has a high fatality rate and poor therapeutic prognosis. CD30 CAR-T-cell therapy has emerged as a new way to treat r/rHL in recent years. However, CD30CAR-T cells are still being explored in clinical trials. To help more patients, this review focuses on current CD30CAR-T-cell advancements as well as clinical breakthroughs in treatment of r/rHL...
October 27, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37883026/evaluating-the-effect-of-immune-checkpoint-inhibitors-on-venous-thromboembolism-in-non-small-cell-lung-cancer-patients
#30
JOURNAL ARTICLE
Xin He, Shan-Na Wei, Wen-Wen Qin, Nan Geng, Bin Li, Shan Song, Ping Wang
OBJECTIVE: Currently, immune checkpoint inhibitors (ICIs) therapy is one of the main methods of treatment in non-small cell lung cancer (NSCLC). This study aimed to explore the risk factors of VTE and evaluate the effect of ICIs on VTE in patients with NSCLC. RESEARCH DESIGN AND METHODS: We retrospectively studied patients with NSCLC who were divided into VTE group and without VTE (Non-VTE) group. We identified the risk factors of VTE in NSCLC patients and evaluated the effect of ICIs on VTE in NSCLC patients...
October 26, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37870168/bridging-the-gap-how-do-we-enroll-more-racial-ethnic-minority-patients-in-hematological-drug-trials
#31
EDITORIAL
Manuel R Espinoza-Gutarra, Sikander Ailawadhi
No abstract text is available yet for this article.
October 23, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37837349/the-role-of-intraarticular-injections-of-hyaluronic-acid-in-joint-pain-relief-in-hemophilic-arthropathy
#32
JOURNAL ARTICLE
E Carlos Rodriguez-Merchan
INTRODUCTION: Chronic knee pain in hemophilic patients is due to joint degeneration associated with hemophilic arthropathy. In addition to appropriate hematological treatment (primary prophylaxis), pharmacologic management and physical medicine and rehabilitation (PMR) should be indicated. When such measures are not sufficient, intraarticular injections (IAIs) of hyaluronic acid (HyA) may be considered. AREAS COVERED: In order to determine whether IAIs of HyA are effective in terms of pain relief in individuals with painful moderate hemophilic arthropathy, a PubMed and Cochrane Library search using 'hemophilia hyaluronic acid' as keywords was performed on 18 July 2023...
October 14, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37830359/redefining-efficacy-and-safety-endpoints-for-chronic-lymphocytic-leukemia-in-the-era-of-targeted-therapy
#33
EDITORIAL
Stefano Molica
No abstract text is available yet for this article.
October 13, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37800996/outcomes-and-long-term-effects-of-hematopoietic-stem-cell-transplant-in-sickle-cell-disease
#34
REVIEW
Zaina Inam, John F Tisdale, Alexis Leonard
INTRODUCTION: Hematopoietic stem cell transplant (HSCT) is the only readily available curative option for sickle cell disease (SCD). Cure rates following human leukocyte antigen (HLA)-matched related donor HSCT with myeloablative or non-myeloablative conditioning are >90%. Alternative donor sources, including haploidentical donor and autologous with gene therapy, expand donor options but are limited by inferior outcomes, limited data, and/or shorter follow-up and therefore remain experimental...
October 6, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37798911/looking-to-the-future-of-gene-therapy-for-hemophilia-a-and-b
#35
EDITORIAL
Radoslaw Kaczmarek, Roland W Herzog
No abstract text is available yet for this article.
October 5, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37670667/clinical-status-of-induction-therapy-incorporating-a-hypomethylating-agent-for-newly-diagnosed-adult-acute-myeloid-leukemia-compared-to-the-standard-7-3-regimen
#36
REVIEW
Akihiro Ohmoto, Shigeo Fuji
INTRODUCTION: Cytarabine and anthracycline combination therapy (7 + 3 regimen) is the standard care for induction chemotherapy in adult patients with acute myeloid leukemia (AML). Although this intensive regimen achieves a high response rate, it is highly toxic, especially in elderly or frail patients. Hypomethylating agents approved initially for high-risk myelodysplastic syndrome had longer survival times than conventional care in elderly patients with newly diagnosed AML...
September 6, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37667498/modifiable-lifestyle-risk-factors-and-survival-after-diagnosis-with-multiple-myeloma
#37
JOURNAL ARTICLE
Simon Cheah, Julie K Bassett, Fiona J Bruinsma, John Hopper, Harindra Jayasekara, Doug Joshua, Robert J MacInnis, H Miles Prince, Melissa C Southey, Claire M Vajdic, Marina T van Leeuwen, Nicole Wong Doo, Simon J Harrison, Dallas R English, Graham G Giles, Roger L Milne
BACKGROUND: While remaining incurable, median overall survival for MM now exceeds 5 years. Yet few studies have investigated how modifiable lifestyle factors influence survival. We investigate whether adiposity, diet, alcohol, or smoking are associated with MM-related fatality. RESEARCH DESIGN AND METHODS: We recruited 760 incident cases of MM via cancer registries in two Australian states during 2010-2016. Participants returned questionnaires on health and lifestyle...
September 4, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37646148/immunogenicity-safety-and-efficacy-of-rurioctocog-alfa-pegol-in-previously-untreated-patients-with-severe-hemophilia-a-interim-results-from-a-phase-3-prospective-multicenter-open-label-study
#38
JOURNAL ARTICLE
Robert F Sidonio, Alexis A Thompson, Flora Peyvandi, Oleksandra Stasyshyn, Seoh Leng Yeoh, Darintr Sosothikul, Ali Bulent Antmen, Caterina Maggiore, Werner Engl, Bruce Ewenstein, Srilatha Tangada
AIM: To determine the immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients (PUPs) with severe hemophilia A (HA). METHODS: This prospective, phase 3 study (NCT02615691) was conducted in PUPs, or patients with ≤ 2 exposure days (EDs) prior to screening, aged ˂6 years with severe HA. The primary endpoint was incidence of FVIII inhibitor development. This protocol-specified interim analysis was conducted after 50 patients had completed ≥ 50 EDs without developing FVIII inhibitors or had developed a confirmed inhibitor at any time...
August 30, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37602448/efficacy-and-safety-evaluation-of-eptacog-beta-coagulation-factor-viia-recombinant-jncw-for-the-treatment-of-hemophilia-a-and-b-with-inhibitors
#39
REVIEW
Steven W Pipe, Amy L Dunn, Guy Young
INTRODUCTION: Bypassing agents (BPAs) are used to treat acute bleeding episodes, manage bleeding during perioperative care, and prophylactically minimize bleed occurrence in persons with hemophilia A or B with inhibitors (PwHABI). However, the effectiveness of BPAs that have been prescribed for the last several decades can be variable, motivating the development of a new recombinant activated factor VII, eptacog beta. AREAS COVERED: This review covers key eptacog beta findings from phase 1b and phase 3 (PERSEPT) clinical trials, which formed the basis for its regulatory approval to treat PwHABI ages 12 and older...
August 21, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37581602/patient-centered-care-in-von-willebrand-disease-are-we-there-yet
#40
JOURNAL ARTICLE
Grace H Tang, Jecko Thachil, Mackenzie Bowman, Carine Bekdache, Paula D James, Michelle Sholzberg
INTRODUCTION: Von Willebrand Disease is the most common inherited bleeding disorder. Paradoxically, affected individuals are often misdiagnosed and experience substantial diagnostic delay. There are sex-specific health disparities in VWD rooted in the stigmatization of vaginal bleeding, which leads to symptom dismissal, lack of timely access to care and lower health-related quality of life. AREAS COVERED: Following the core elements of patient-centered care - respect for patient preferences, values, and needs, we describe the current state of VWD care...
August 15, 2023: Expert Review of Hematology
journal
journal
42167
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.